You are here

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Last updated on July 25, 2019

FOR MORE INFORMATION
Study Location
MedPharmics, LLC
Metairie, Louisiana, 70006 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female adults 65 years of age or greater.

2. Adults determined by clinical assessment, including medical history and clinical
judgment, to be eligible for the study, including adults with preexisting stable
disease, defined as disease not requiring significant change in therapy in the
previous 6 weeks or hospitalization for worsening disease within 12 weeks before
receipt of investigational product.

3. Female subject of nonchildbearing potential; male subject not able to father children
or who is able to father children and willing to use a highly effective method of
contraception.

4. Male or female adults who meet 1 of the following:

1. Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to
5 years prior to vaccination in the study, and no prior 13vPnC vaccination
(Cohort A).

2. Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in
the study, and no prior PPSV23 vaccination (Cohort B).

3. Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or
equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Serious chronic disorder including metastatic malignancy, severe chronic obstructive
pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with
or without dialysis, clinically unstable cardiac disease, or any other disorder that,
in the investigator's opinion, excludes the subject from participating in the study.

2. History of microbiologically proven invasive disease caused by S pneumoniae.

NCT03835975
Pfizer
Recruiting
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now